FDA Approves Aemcolo (rifamycin) to Treat Travelers’ Diarrhea Print this page November 16, 2018 — The U.S. Food and Drug Administration today approved Aemcolo (rifamycin), an antibacterial drug indicated for the treatment of adult patients with travelers’ diarrhea caused by noninvasive strains of Escherichia coli (E. coli), not complicated by fever or blood in the… Read More »
FDA Approves Hyrimoz (adalimumab-adaz), a Biosimilar to Humira Print this page Holzkirchen, Germany, October 31, 2018 – Sandoz, a Novartis division and the pioneer and global leader in biosimilars, today announced that the US Food and Drug Administration (FDA) approved its biosimilar, Hyrimoz (adalimumab-adaz). The FDA granted approval for the treatment of rheumatoid arthritis (RA),… Read More »
FDA Approves Bijuva (estradiol and progesterone) Capsules for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause Print this page BOCA RATON, Fla.–(BUSINESS WIRE)–Oct. 29, 2018– TherapeuticsMD, Inc, an innovative women’s healthcare company, today announced that the United States Food and Drug Administration (FDA) has approved Bijuva (estradiol and progesterone) capsules, 1 mg/100… Read More »
Sept. 28, 2018 — The FDA has approved the third of a new type of drug to prevent migraine headaches in adults. Galcanezumab-gnlm (Emgality) targets calcitonin gene-related peptide (CGRP), a molecule that’s produced in nerve cells of the brain and spinal cord. The FDA approved two other CGRP drugs for migraine — erenumab (Aimovig) and fremanezumab-vfrm… Read More »